Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3

Cell Death and Disease

Volumn 7, Issue 11, 2016, Pages

  Ao, Xiang ^a   Nie, Peipei ^a   Wu, Baoyan ^b   Xu, Wei ^a   Zhang, Tao ^b   Wang, Songmao ^b   Chang, Haocai ^b   Zou, Zhengzhi ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTH CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 20B; PACLITAXEL; STEROID RECEPTOR COACTIVATOR 3; MIRN17 MICRORNA, HUMAN; MIRN20 MICRORNA, HUMAN; NCOA3 PROTEIN, HUMAN; TAMOXIFEN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER RESISTANCE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MICRORNAS; NUCLEAR RECEPTOR COACTIVATOR 3; PACLITAXEL; RNA, MESSENGER; TAMOXIFEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84995407538     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.367     Document Type: Article

References (43)

1. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: current status and future directions. CA Cancer J Clin 2015; 65: 345-383.
2. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of taxol resistance related to microtubules. Oncogene 2003; 22: 7280-7295.
3. Vaidyanathan A, Sawers L, Gannon AL, Chakravarty P, Scott AL, Bray SE et al. ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells. Br J Cancer 2016; 115: 431-441.
4. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118-17125.
5. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277: 965-968.
6. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res 1998; 4: 2925-2929.
7. Ochnik AM, Peterson MS, Avdulov SV, Oh AS, Bitterman PB, Yee D. Amplified in breast cancer regulates transcription and translation in breast cancer cells. Neoplasia 2016; 18: 100-110.
8. Zou Z, Luo X, Nie P, Wu B, Zhang T, Wei Y et al. Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun 2016; 478: 227-233.
9. Mo P, Zhou Q, Guan L, Wang Y, Wang W, Miao M et al. Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling. Oncogene 2015; 34: 3935-3945.
10. Iwase H, Omoto Y, Toyama T, Yamashita H, Hara Y, Sugiura H et al. Clinical significance of AIB1 expression in human breast cancer. Breast Cancer Res Treat 2003; 80: 339-345.
11. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 2010; 36: 224-229.
12. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
13. Dihge L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L et al. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat 2008; 109: 255-262.
14. He LR, Liu MZ, Li BK, Rao HL, Deng HX, Guan XY et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci 2009; 100: 1591-1596.
15. De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A et al. miR-205-5pmediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis 2015; 6: e1823.
16. Sheng L, He P, Yang X, Zhou M, Feng Q. miR-612 negatively regulates colorectal cancer growth and metastasis by targeting AKT2. Cell Death Dis 2015; 6: e1808.
17. Roca-Alonso L, Castellano L, Mills A, Dabrowska AF, Sikkel MB, Pellegrino L et al. Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in betaadrenergic signaling and enhances apoptosis. Cell Death Dis 2015; 6: e1754.
18. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159.
19. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011; 286: 19127-19137.
20. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285: 21496-21507.
21. Hu Y, Qiu Y, Yague E, Ji W, Liu J, Zhang J. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis 2016; 7: e2291.
22. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
23. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875-886.
24. Qu Y, Zhang H, Duan J, Liu R, Deng T, Bai M et al. MiR-17-5p regulates cell proliferation and migration by targeting transforming growth factor-beta receptor 2 in gastric cancer. Oncotarget 2016; 7: 33286-33296.
25. Ma H, Pan JS, Jin LX, Wu J, Ren YD, Chen P et al. MicroRNA-17 ∼ 92 inhibits colorectal cancer progression by targeting angiogenesis. Cancer Lett 2016; 376: 293-302.
26. Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PloS One 2009; 4: e7629.
27. Ahmad A, Ginnebaugh KR, Sethi S, Chen W, Ali R, Mittal S et al. miR-20b is up-regulated in brain metastases from primary breast cancers. Oncotarget 2015; 6: 12188-12195.
28. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387.
29. Torres-Arzayus MI, Font DMJ, Yuan J, Vazquez F, Bronson R, Rue M et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004; 6: 263-274.
30. Chu B, Liu F, Li L, Ding C, Chen K, Sun Q et al. A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell Death Dis 2015; 6: e1686.
31. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
32. Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G. miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget 2015; 6: 19006-19016.
33. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y et al. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci USA 2010; 107: 8231-8236.
34. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V et al. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010; 224: 242-249.
35. Park SL, Cho TM, Won SY, Song JH, Noh DH, Kim WJ et al. MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncol Rep 2015; 34: 1605-1612.
36. Luo X, Yao J, Nie P, Yang Z, Feng H, Chen P et al. FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation. Oncotarget 2016; 7: 26480-26495.
37. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PloS One 2014; 9: e97719.
38. Jiang S, Zou Z, Nie P, Wen R, Xiao Y, Tang J. Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells. PloS One 2015; 10: e132880.
39. Zou ZZ, Nie PP, Li YW, Hou BX, Rui-Li, Shi XP et al. Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer. Oncotarget 2015 (e-pub ahead of print).
40. Nie P, Hu W, Zhang T, Yang Y, Hou B, Zou Z. Synergistic induction of erlotinib-mediated apoptosis by resveratrol in human non-small-cell lung cancer cells by down-regulating survivin and up-regulating PUMA. Cell Physiol Biochem 2015; 35: 2255-2271.
41. Ma N, Zhang W, Qiao C, Luo H, Zhang X, Liu D et al. The tumor suppressive role of MiRNA-509-5p by targeting FOXM1 in non-small cell lung cancer. Cell Physiol Biochem 2016; 38: 1435-1446.
42. Nilsson UW, Dabrosin C. Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res 2006; 66: 4789-4794.
43. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy 2012; 8: 1798-1810.